Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Ravi K. Anchoori"'
Autor:
Ravi K Anchoori, Ssu-Hsueh Tseng, Hua-Ling Tsai, Vikrant Palande, Michelle A Rudek, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0305710 (2024)
There is an urgent unmet need for more targeted and effective treatments for advanced epithelial ovarian cancer (EOC). The emergence of drug resistance is a particular challenge, but small molecule covalent inhibitors have promise for difficult targe
Externí odkaz:
https://doaj.org/article/2db63bf16e0e4c7bacaecfd447382c57
Autor:
Ravi K Anchoori, Vidyasagar Anchoori, Brandon Lam, Ssu-Hsueh Tseng, Samarjit Das, Fernanda Carrizo Velasquez, Balasubramanyam Karanam, Deepika Poddatoori, Ramesh Patnam, Michelle A Rudek, Yung-Nien Chang, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 18, Iss 6, p e0285221 (2023)
Bortezomib has been successful for treatment of multiple myeloma, but not against solid tumors, and toxicities of neuropathy, thrombocytopenia and the emergence of resistance have triggered efforts to find alternative proteasome inhibitors. Bis-benzy
Externí odkaz:
https://doaj.org/article/9b4e3a1ede114e78983838d19f4e8731
Autor:
Ruey-Shyang Soong, Ravi K. Anchoori, Richard B. S. Roden, Rou-Ling Cho, Yi-Chan Chen, Sheng-Chieh Tseng, Yun-Li Huang, Po-Cheng Liao, Yu-Chiau Shyu
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
Abstract Background According to GLOBOSCAN, hepatocellular carcinoma (HCC) claimed 782,000 lives in 2018. The tyrosine kinase inhibitor sofafenib is used to treat HCC, but new anticancer agents targeting different pathways are urgently needed to impr
Externí odkaz:
https://doaj.org/article/44a667359ad24cdaa8fc5e8ea4089343
Autor:
Ravi K Anchoori, Logan George, Ssu-Hsueh Tseng, Brandon Lam, Srinidhi Polkampally, Anjali D Amiano, Palmer Foran, Hannah Tsingine, Harideep Samanapally, Fernanda Carrizo Velasquez, Samarjit Das, Deyin Xing, Ahmad Bin Salam, Balasubramanyam Karanam, Chien-Fu Hung, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 16, Iss 9, p e0256937 (2021)
Bortezomib and the other licensed 20S proteasome inhibitors show robust activity against liquid tumors like multiple myeloma, but have disappointed against solid tumors including ovarian cancer. Consequently, interest is mounting in alternative non-p
Externí odkaz:
https://doaj.org/article/a191fb5eadb24586b1e67b55b0cdb07d
Autor:
Ravi K Anchoori, Marietta Tan, Ssu-Hsueh Tseng, Shiwen Peng, Ruey-Shyang Soong, Aliyah Algethami, Palmer Foran, Samarjit Das, Chenguang Wang, Tian-Li Wang, Hong Liang, Chien-Fu Hung, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 15, Iss 1, p e0227727 (2020)
We sought to design ubiquitin-proteasome system inhibitors active against solid cancers by targeting ubiquitin receptor RPN13 within the proteasome's 19S regulatory particle. The prototypic bis-benzylidine piperidone-based inhibitor RA190 is a michae
Externí odkaz:
https://doaj.org/article/d0a6399b2dc8409e97710fa3b4fd75f6
Autor:
Ravi K. Anchoori, Rosie Jiang, Shiwen Peng, Ruey-shyang Soong, Aliyah Algethami, Michelle A. Rudek, Nicole Anders, Chien-Fu Hung, Xiang Chen, Xiuxiu Lu, Olumide Kayode, Marzena Dyba, Kylie J. Walters, Richard B. S. Roden
Publikováno v:
ACS Omega, Vol 3, Iss 9, Pp 11917-11929 (2018)
Externí odkaz:
https://doaj.org/article/ddb3d390b0824e9bb143313880ac9c72
Autor:
Rosie T. Jiang, Anna Yemelyanova, Deyin Xing, Ravi K. Anchoori, Jun Hamazaki, Shigeo Murata, Jeffrey D. Seidman, Tian-Li Wang, Richard B. S. Roden
Publikováno v:
Journal of Ovarian Research, Vol 10, Iss 1, Pp 1-12 (2017)
Abstract Background Ovarian carcinoma is highly dependent on the ubiquitin proteasome system (UPS), but its clinical response to treatment with the proteasome inhibitor bortezomib has been disappointing. This has driven exploration of alternate appro
Externí odkaz:
https://doaj.org/article/9ff98f8274cc4f019b69a84610a69d51
Publikováno v:
Cancer Research. 83:4941-4941
Glioblastoma (GBM) is an aggressive and deadly brain cancer with a one-year median survival due to the lack of effective targeted treatments. Our goal is to develop a small molecule inhibitor targeting RPN13 protein in the 19S proteasome complex as a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f246362029b995c148114b617b717b6f
https://doi.org/10.1158/1538-7445.am2023-4941
https://doi.org/10.1158/1538-7445.am2023-4941
Autor:
Ssu-Hsueh Tseng, Ahmad Bin Salam, Anjali D. Amiano, Fernanda Carrizo Velasquez, Hannah Tsingine, Brandon Lam, Srinidhi Polkampally, Chien Fu Hung, Balasubramanyam Karanam, Deyin Xing, Samarjit Das, Harideep Samanapally, Palmer Foran, Ravi K. Anchoori, Logan George, Richard B.S. Roden
Publikováno v:
PLoS ONE, Vol 16, Iss 9, p e0256937 (2021)
PLoS ONE
PLoS ONE
Bortezomib and the other licensed 20S proteasome inhibitors show robust activity against liquid tumors like multiple myeloma, but have disappointed against solid tumors including ovarian cancer. Consequently, interest is mounting in alternative non-p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e20895463cbbd03f0a62cea02a68e78d
https://doaj.org/article/a191fb5eadb24586b1e67b55b0cdb07d
https://doaj.org/article/a191fb5eadb24586b1e67b55b0cdb07d
Autor:
Ruey Shyang Soong, Po Cheng Liao, Yun Li Huang, Yu-Chiau Shyu, Rou Ling Cho, Yi Chan Chen, Sheng Chieh Tseng, Ravi K. Anchoori, Richard B.S. Roden
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
BMC Cancer
BMC Cancer
Background According to GLOBOSCAN, hepatocellular carcinoma (HCC) claimed 782,000 lives in 2018. The tyrosine kinase inhibitor sofafenib is used to treat HCC, but new anticancer agents targeting different pathways are urgently needed to improve outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1132d2b000ebbd6a1a54bf1333098c3f
https://doi.org/10.21203/rs.2.18702/v2
https://doi.org/10.21203/rs.2.18702/v2
